Canaccord analyst Edward Nash raised the firm’s price target on Verona Pharma (VRNA) to $106 from $72 and keeps a Buy rating on the shares. The firm said during the quarter, Ohtuvayre product sales revenue was $71.3M, and beat their expectation of $47M, as well as the consensus of $53.1M. 1Q25 was the second full quarter of Ohtuvayre’s launch, and sales revenue showed a 95% sequential growth. Canaccord is encouraged by this result, and believes Ohtuvayre will continue to see fast growth in sales revenue for the rest of the year and beyond.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma’s Strong Market Performance and Strategic Advancements Justify Buy Rating and Increased Price Target
- Verona Pharma price target raised to $85 from $75 at H.C. Wainwright
- Verona Pharma Reports Strong Q1 2025 Earnings
- Verona Pharma’s Earnings Call: O2VERE’s Success Fuels Optimism
- Verona Pharma reports Q1 EPS (2c), consensus (3c)